November, 2023

Remove biopharma-healthcare
article thumbnail

Should Biopharma C-Suites Still Engage With China? A Harvard Business School Healthcare Alumni Association Q&A with Professor F. Warren McFarlan

PharmExec

An overview of what biopharma C-Suites and their boards should consider when engaging with government and business leaders from China, the world’s second largest economy.

article thumbnail

One Size Doesn’t Fit All for Access to Emerging Markets

PM360

While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., market, emerging markets present great opportunities for biotech and pharmaceutical companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Single-use bioprocessing market to value $84.14bn by 2032

European Pharmaceutical Review

billion by 2032, according to Towards Healthcare. Automation in biopharma automation is expected to dominate the single-use bioprocessing industry within the next five years” Automation offers numerous benefits to the biopharmaceutical manufacturing process.

article thumbnail

Genentech’s Chief Marketing Officer Talks Marketing’s New Role and Data-Driven Content

PM360

I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content. Pooja Ojala: How do you approach marketing to adapt to today’s healthcare landscape?

Marketing 105
article thumbnail

Uncovering the Hidden Gems within Your Datasets

PM360

“The axiom ‘Most people use statistics like a drunk man uses a lamp post; more for support than illumination’ is especially applicable in today’s era of nearly unlimited data,” says David Marks, PhD, MSc, VP, Medical Director, Elevate Healthcare. However, correlation does not always equal causation between variables.

article thumbnail

Best practices for AI and ML use across the drug discovery and development lifecycle

Clarivate

Romeo Radman, Vice President, Life Sciences & Healthcare, Product and Strategy, Clarivate “Real” intelligence fills the artificial intelligence gaps Rather than completely replacing conventional methods or wisdom, AI/ML tools create new efficiencies and accelerate understanding and decisions.

article thumbnail

Innovation doesn’t always need to be radical: an example in diabetes

Clarivate

Most clients we work with are keen to communicate that their product is innovative. Of course they are. Innovation is important, right? Well, it is, but only if it benefits patients. 1] And, sometimes, it’s the small, incremental developments that provide the most benefit.